Calithera Biosciences Highlights Results From Six

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Calithera Biosciences Highlights Results From Six Preclinical Abstracts at the American Association for Cancer Research Annual Meeting 2015

-Potential Biomarker Response to CB-839 Among KRAS and EGFR Mutant Cell Lines

-Synergy of CB-839 with Signal Transduction Pathways

SOUTH SAN FRANCISCO, Calif., April 21, 2015 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA ) a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, today will announce preclinical data for its lead anti-cancer therapeutic candidate, CB-839, Calithera's novel, orally bioavailable glutaminase inhibitor, at the American Association for Cancer Research, taking place April 18-22, 2015 in Philadelphia, Pennsylvania. CB-839 is a potent, selective, orally bioavailable glutaminase inhibitor in phase I clinical trials.

"We have identified KRAS and EGFR mutation status as potential biomarkers correlated to enhanced sensitivity of CB-839, which could ultimately direct our development of CB-839 in non-small cell lung cancer. In addition, based on our synergy studies, CB-839 in combination with signal transduction inhibition may offer a novel therapeutic strategy for the treatment of non-small cell lung cancer and renal cell carcinoma," said Susan Molineaux, PhD, President and Chief Executive Officer of Calithera.

Preclinical data will be presented by Lindsey Boroughs from the laboratory of Ralph Debaradinis at the University of Texas Southwestern in an oral session titled, "Evaluation of the glutaminase inhibitor CB-839 in non-small cell lung cancer," on April 21, 2015 (Abstract #4710). In this session, data will be presented demonstrating that lung cancer cell lines carrying EGFR or KRAS mutations have enhanced sensitivity to CB-839. Additional preclinical data from Calithera will be presented by Frank Parlati, Senior Director of Biology, in an oral session titled "CB-839, a selective glutaminase inhibitor, synergizes with signal transduction pathway inhibitors to enhance anti-tumor activity," (Abstract #4711). Signaling through mTOR is down regulated by CB-839, demonstrating a relationship between signal transduction pathways and cancer metabolism. CB-839 also synergizes with the mTOR inhibitor everolimus in renal clear cell carcinoma lines. In addition, CB-839 has synergistic activity with the MEK inhibitor selumetinib in KRAS mutant lung cancer cell lines both in vitro and in vivo, and with the EGFR inhibitor erlotinib in EGFR mutant lung cancer cell lines as well as in erlotinib-resistant EGFR mutant animal models lacking the T790M mutation.

CB-839 was also the subject of a poster presented by Calithera's collaborator Arimichi Okazaki from the Laboratory of Othon Iliopoulos at the Massachusetts General Hospital titled, "Glutaminase inhibitors suppress pyrimidine synthesis and promote DNA replication stress in Von Hippel-Lindau (VHL) deficient human renal cells (Abstract #1123)." The data demonstrate that CB-839 induces double stranded breaks in VHL deficient renal cell carcinoma cells and that PARP (Poly ADP-ribose polymerase) inhibitors synergize with CB-839 in these cells.

Three additional presentations at the meeting include:

Targeting glucose and glutamine regulated BCL2 family members for multiple myeloma therapy
Abstract #972
Presenter: Richa Bajpai, Winship Cancer Institute, Emory University
Sunday, April 19, 2015

CB839, an orally bioavailable glutaminase inhibitor, shows potent antitumor activity in vitro against models of soft tissue sarcoma and chondrosarcoma
Abstract #4450
Presenter: Tahir Sheikh, Laboratory of Gary Schwartz, Columbia University
Tuesday, April 21, 2015

A new anticancer strategy based on inhibiting mitochondrial proline dehydrogenase (PRODH) and exploiting synthetic lethal interactions with p53 restoration and/or glutaminase (GLS1) inhibition
Abstract #5402
Presenter: Gary Scott, Laboratory of Christopher Benz, Buck Institute
Wednesday, April 22, 2015

The meeting abstracts can be viewed online through the AACR website at www.aacr.org .

About Calithera Biosciences

Calithera Biosciences is a clinical-stage company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology. Calithera's lead clinical candidate, CB-839, is a first-in-class inhibitor of glutaminase, a critical enzyme in tumor metabolism, and is currently being tested in patients with solid and hematological cancers. Calithera Biosciences is headquartered in South San Francisco. For more information about Calithera Biosciences, please visit www.calithera.com .

Forward Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "anticipate," "estimate," "intend," "poised" and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. These statements include those related to Calithera's development of CB-839 in non-small cell lung cancer and the potential therapeutic strategy for of CB-839. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. The potential product candidates that Calithera develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all. In addition, clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release. Such product candidates may not be beneficial to patients or successfully commercialized. The failure to meet expectations with respect to any of the foregoing matters may have a negative effect on Calithera's stock price. Additional information concerning these and other risk factors affecting Calithera's business can be found in Calithera's Annual Report on Form 10-K for the fiscal year ended December 31, 2014 and other periodic filings with the Securities and Exchange Commission at www.sec.gov . These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, Calithera disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.

Jennifer McNealey 650-870-1071

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 410

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
Championing Change: USTA Mid-Atlantic Gala's Impact

Updated Category News Views 277

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 235

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 284

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 318

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 103

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
KINGRVER Boosts RV Comfort with New Water Heater Lineup

Updated Category News Views 233

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 0

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 203

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
Princess Cruises Launches New Era at Celebration Key

Updated Category News Views 153

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Continue Reading

Top 5 Most Recently Viewed Articles

Fokus Mining Corporation Pursues $1.5 Million Funding Initiative

Updated Category News Views 194

Fokus Mining Corporation Reveals New Funding Initiative Fokus Mining Corporation (TSX.V: FKM) and OTCQB: FKMCF has announced an exciting plan to raise $1.5 million through a private placement. This move is particularly important as it highlights the company's dedication to advancing its projects and boosting its operational capabilities. Overview of the Private Placement...

Continue Reading
Empowering Investors: Lions Gate Entertainment Corp. Class Action

Updated Category News Views 102

Understanding the Investigation into Lions Gate Entertainment Corp. Lions Gate Entertainment Corp. is facing serious scrutiny due to concerns about possible misrepresentation of crucial business information to shareholders. This situation has sparked a thorough examination of their practices, especially following a recent lawsuit filed against the company. Details of the...

Continue Reading
Revolutionary Tool Simplifies Muriatic Acid Application for Pools

Updated Category News Views 137

Innovative Solution for Pool Maintenance Maintaining a clean and attractive swimming pool is essential for many homeowners. One common challenge faced during pool maintenance is dealing with stubborn stains that can mar the pool's beauty. To address this issue, an inventive mind has introduced a unique tool known as STICK-A-STAIN, designed specifically for applying...

Continue Reading
Landsnet Reports Strong Half-Year Results with Future Growth in Sight

Updated Category News Views 163

Landsnet's Half-Year Financial Performance Overview Landsnet recently released its financial report for the period ending in June 2025, showing noteworthy progress. The company reported a profit of USD 11.5 million, supporting its robust standing in the market. Key Financial Highlights The interim financial results indicate a decrease in profit compared to last year,...

Continue Reading
KabaFusion and Tennr Join Forces to Transform Home Infusion Care

Updated Category News Views 222

KabaFusion and Tennr Join Forces to Transform Home Infusion Care Strategic Partnership Uses AI to Advance Patient Care, Empower Clinicians, and Optimize Home Infusion Services KabaFusion, a leading name in home infusion, has announced its strategic partnership with Tennr, a cutting-edge healthcare technology firm known for automating referral-based care. This...

Continue Reading